Comprehensive Guide to Urapidil (CAS 34661-75-1)
Table of Contents
- 1. Technical Specifications & Comparative Analysis
- 2. Detailed Applications
- 3. Usage Guidelines
- 4. Case Studies
- 5. Client Implementation Examples
- 6. Request Information
1. Technical Specifications & Comparative Analysis
| Parameter | Urapidil | Prazosin | Terazosin |
|---|---|---|---|
| CAS Number | 34661-75-1 | 19216-56-9 | 63590-64-7 |
| Molecular Formula | C20H29N5O3 | C19H21N5O4 | C19H25N5O4 |
| Molecular Weight | 387.48 g/mol | 419.41 g/mol | 423.44 g/mol |
| Appearance | White crystalline powder | White solid | Off-white powder |
2. Detailed Applications
Primary Therapeutic Uses:
- Hypertension management (acute/chronic)
- Benign prostatic hyperplasia (BPH) treatment
- Post-surgical blood pressure control
3. Usage Guidelines
Administration Protocols:
| Formulation | Dosage | Frequency |
|---|---|---|
| Intravenous | 25-50 mg | Every 2-5 minutes |
| Oral | 30-90 mg | Twice daily |
4. Case Studies
Clinical Trial Results:
| Study Duration | Patient Group | Efficacy Rate |
|---|---|---|
| 12 weeks | Stage 2 Hypertension | 84% BP normalization |
5. Client Implementation Examples
Pharmaceutical Manufacturer A (Germany):
- Application: Hypertension crisis management
- Implementation: Hospital emergency protocol
- Outcome: 40% reduction in complications
Research Institution B (USA):
- Application: BPH symptom relief
- Implementation: Long-term therapy
- Outcome: 68% symptom improvement
6. Request Information
Contact our technical specialists:
Email: info@vivalr.com
Phone: (86) 15866781826
Request product specifications, COA, or formulation guidance:
| Document Type | Available Formats |
|---|---|
| Certificate of Analysis | PDF, Hard Copy |



评论
目前还没有评论。